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Abstract: Isoprostanes (IsoPs) are key biomarkers for investigating the role of free radical 
generation in the pathogenesis of human
 disorders. To solve IsoPs-related problems with 
regard to isoprostanes, analytical tools are required. This paper reviews the problems and 
trends in this field focusing on the methodology for assaying biomarkers in exhaled breath 
condensate (EBC) samples. A large amount of work has been done in the qualitative and 
quantitative  analysis  of  IsoPs,  but  a  standardized  method  has  yet  to  emerge.  The 
methodologies described differ, either in the sample preparation steps or in the detection 
techniques, or both. Requiring a number of chromatographic steps, the relevant extraction 
and  purification  procedures  are  often  critical  and  time-consuming,  and  they  lead  to  a 
substantial  loss  of  target  compounds.  Recent  data  show  that  EBC  is  a  promising 
non-invasive tool for the evaluation of different diseases. Two main analytical approaches 
have  been  adopted  for  IsoPs  measurement:  immunological  methods  and  mass 
spectrometry. The methodologies for the extraction, purification and analysis of IsoPs in 
EBC samples are presented.  
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1. Introduction 
In  recent  years,  oxidative  stress  has  been  implicated  in  various  pathological  situations.  The 
difficulty is to choose a convenient marker for evaluating its importance in vivo, because of analytical 
problems of specificity and sensitivity. The oxidized lipids formed during lipid peroxidation, illustrate 
these problems (Figure 1). Among these markers are ‘primary’ products such as hydroperoxides, or 
‘secondary’ products such as malondialdehyde (MDA), 4-hydroxynonenal (4-HNE) and isoprostanes 
(IsoPs). They are all measurable in biological fluids, but analytical procedures used are sometimes 
complex and require sample preparation involving extraction and purification steps. IsoPs are certainly 
the most specific markers of lipid peroxidation but they are also most difficult to measure. Several 
comprehensive reviews providing information on the biochemistry of IsoPs and their utilization as a 
marker  of oxidative stress have been published in the last 10 years [1–5]. Numerous assays have 
recently been developed: some, like gas or liquid chromatography coupled with mass spectrometry, are 
the  ‘gold  standard’  methods,  enabling  different  IsoPs  to  be  measured  but  they  required  special 
apparatus. Others, like immunoassay methods, measure one IsoP—they are simpler to perform and are 
accessible to a greater number of laboratories but they are still lacking in specificity. 
Figure 1. Main products of Reactive Oxygen Species activity. 
 
The  materials  used  to  measure  isoprostanes  and  their  metabolites  are  urine  [6–9],  blood 
plasma [8,10–11],  cerebrospinal  fluid  [12],  exhaled  breath  condensate  [13–17],  bronchopulmonary 
lavage (BAL) [18], amniotic fluid [19], meconium and tissues [20]. Several systemic diseases, such as 
atherosclerosis,  hypertension  and  others,  were  described  to  increase  serum  and  urine  8-isoPGF2α 
level [21]. The IsoP levels found in different specimen are summarized in Figure 2. 
The discovery of IsoPs has important implications for medicine: 
•  It has now been established that measurement of IsoPs is the most reliable approach to the 
assessment of oxidative stress status in vivo, providing an important tool for exploring the role 
of oxidative stress in the pathogenesis of human disease; 
•  products of the IsoPs pathway have been found to exert potent biological actions and therefore 
may be pathophysiological mediators of disease. Int. J. Mol. Sci. 2010, 11                      
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Figure 2. Isoprostane levels in different specimen. 
 
In the mid-1990s a new, non-invasive sample collection technique for investigating the lungs was 
brought  to  the  attention  of  researchers:  exhaled  breath  condensate  (EBC).  It  shows  the  extent  of 
interest that more than 80 original articles have been published on this subject in the last five years. 
Many substances are found in expired breath that are detectable in the liquid that can be obtained by 
cooling (i.e., condensing) it. The advantages of this method are that it is non-invasive, convenient, and 
can be carried out on mechanically ventilated patients as well as on children  
There  are  many  compounds  that  are  determined  in  EBC:  volatile  compounds  (VOCs)  [22], 
non-volatile compounds (very low molecular weight compounds, low molecular weight compounds, 
polypeptides, proteins, nucleic acids), non-volatile compounds derived from volatile compounds, and 
miscellaneous  others  (lipid  mediators,  inorganic  molecules,  organic  molecules,  redox  relevant 
molecules, pH relevant molecules, cytokines, chemokines). It is important to note that some clearly 
non-volatile compounds found in EBC may be derivatives of volatiles. For example, nitrate (NO3
−) 
and nitrite (NO2
−), ionized and therefore not volatile, may arise in EBC in part from a reaction of 
volatile nitric oxide gas (NO) after reaction with oxygen [23]. Volatiles such as acetic acid, formic acid 
and ammonia are found in much higher concentrations in EBC than non-volatile constituents, and are 
thus much easier to measure.  
The non-volatile constituents of EBC make up a broad category, containing molecules as small as 
sodium ions (Na
+) and as large as immunoglobulins. There are numerous publications in the literature 
presenting an individual compound that has been found in EBC (often relying on one assay) with 
levels  depending  upon  the  disease  state,  and  comments  that  the  biomarker  may  be  valuable  in 
managing the disease of interest. The most widely studied substance is hydrogen peroxide, which is a 
marker of oxidative stress: Its level in EBC is elevated in numerous inflammatory diseases.  
A search of the Information Sciences Institute (ISI Web of Knowledge) revealed some 855 scientific 
publications concerning EBC (to June 14, 2010) in the peer-reviewed literature. However one should 
expect that even 100 more publications are identified in the non-peer-reviewed literature. Although one 
of  the  first  papers  was  published  back  in  1980,  the  number  of  publications  exhibiting  increased 
concern regarding EBC has risen fairly steadily over the past 10 years (see Figure 3).  Int. J. Mol. Sci. 2010, 11                      
 
4634 
Figure 3. Number of publications on EBC over the past 10 years. 
 
The number of articles on EBC analysis has increased tenfold in the last 10 years. 
2. Isoprostanes as Biomarkers of Diseases 
The measurement of isoprostanes (IsoPs) in biological fluids and/or tissue specimens has important 
clinical implications. Oxidative stress is the hallmark of various chronic inflammatory lung diseases. 
Increased concentrations of reactive oxygen species (ROS) in the lungs of such patients are reflected 
by elevated concentrations of oxidative stress markers in the breath, airways, lung tissue and blood. 
Traditionally, the measurement of these biomarkers has involved invasive procedures to procure the 
samples or to examine the affected compartments, to the patient's discomfort. As a consequence, there 
is a need for less or non-invasive approaches to measure oxidative stress. The collection of exhaled 
breath condensate (EBC) has recently emerged as a non-invasive sampling method for the real-time 
analysis  and  evaluation  of  oxidative  stress  biomarkers  in  the  lower  respiratory  tract  airways. 
Biomarkers  of  oxidative  stress  such  as  H2O2,  IsoPs,  malondialdehyde,  4-hydroxy-2-nonenal, 
antioxidants, glutathione and nitrosative stress markers such as nitrate/nitrite and nitrosated species 
have all been successfully measured in EBC.  
Measurements of IsoPs in EBC have several advantages over other markers of oxidative stress: 
They are chemically stable, are formed in vivo, are specific to lipid peroxidation, and are used to define 
the clinical pharmacology of antioxidants [24]. 
8-IsoP concentration  was found to  be elevated in asthma [30–33],  COPD [34], interstitial lung 
disease [35], cystic fibrosis (CF) [36], acute respiratory distress syndrome (ARDS) [28], pulmonary 
sarcoidosis [37], obstructive sleep apnea [38], and also in healthy subjects after ozone-inhalation [39]. 
However, in asthma, the observed increase in the EBC 8-isoPGF2α level was related to the severity of 
the disease, and the relative resistance of 8-isoPGF2α to steroids has been reported in children with 
asthma  exacerbation  [31–33].  8-isoPGF2α  levels  were  also  found  to  be  elevated  during  COPD 
exacerbation, but fell after treatment [34]. Differencies between IsoPs concentrations in healthy and 
non-healthy subjects are presented in Figure 4. 
 Int. J. Mol. Sci. 2010, 11                      
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Figure 4. Concentration of 8-isoPGF2α in EBC in healthy and non-healthy subjects [25–29]. 
 
Exhaled breath condensate is obtained from both adult and child patients suffering from various 
pulmonary  diseases  such  as  asthma,  cystic  fibrosis,  chronic  obstructive  pulmonary  disease,  and 
interstitial lung diseases.  
Several in vitro markers of oxidative stress are available, but most are of limited value in vivo 
because they lack sensitivity and/or specificity or require invasive methods. IsoPs are prostaglandin 
(PG)-like  substances  that  are  produced  in vivo  independently  of cyclooxygenase  (COX)  enzymes, 
primarily by free radical-induced peroxidation of arachidonic acid (Figure 5).  
Figure 5. Products of free radical-induced peroxidation of arachidonic acid. 
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An important aspect of the discovery of IsoPs is that their measurement has emerged as one of the 
most  reliable  approaches  to  assess  oxidative  stress  status  in  vivo,  providing  an  important  tool  to 
explore the role of oxidative stress in the pathogenesis of human disease. 
Isoprostanes F2α are a group of 64 compounds isomeric  in structure  to cyclooxygenase-derived 
PGF2α.  Other  products  of  the  IsoPs  pathway  are  also  formed  in  vivo  by  rearrangement  of  labile 
PGH2-like IsoP intermediates. 
The discovery of IsoPs has important implications for medicine: First, it has now been established 
that  measurement  of  IsoPs  is  the  most  reliable  approach  to  assess  oxidative  stress  status  in  vivo, 
providing  an  important  tool  to  explore  the  role  of  oxidative  stress  in  the  pathogenesis  of  human 
disease. In addition, products of the IsoP pathway have been found to exert potent biological actions 
and may therefore be pathophysiological mediators of disease [40]. 
2.1. Applications of Measurement of 8-IsoPGF2α in Lung Diseases 
Although measurement of 8-isoPGF2α in EBC is a useful noninvasive approach for exploring the 
role  of  oxidative  stress in  lung  diseases  (this  technique  might  provide  important  insights  into  the 
understanding of the clinical pharmacology of antioxidants and might be useful for monitoring the 
effects of pharmacological therapy [41]), little is known about whether the concentration of oxidative 
stress markers is also affected by some systemic diseases (atherosclerosis, diabetes, etc.). Another 
unanswered question is the locus of the origin of these markers in the respiratory tract. No positive 
correlation between blood and EBC concentrations was seen in the studied markers. No significant 
difference was seen in the level of the markers at different breathing frequencies.  
Markers of oxidative stress in the EBC seem to be independent of blood levels, which confirms 
their importance for lung disorders. The results are compatible with the hypothesis that the source of 
increased EBC markers is the lung parenchyma.  
2.1.1. Allergy 
Allergic rhinitis is a common disease that is reported to affect 10–40% of the global population and 
its  prevalence  is  increasing  in  both adults and children.  There are significant  differences  between 
documented  studies  on  8-IsoP  measurement  in  patients  with  this  disease.  One  study  shows  no 
differences between the study groups in the levels of 8-IsoP in EBC of controls and allergic rhinitis 
patients [42], whereas in another 8-IsoP was significantly increased in a group of patients with allergic 
rhinitis (mean 43.6 pg/mL) than in healthy subjects (mean 18.6 pg/mL) [43]. 
2.1.2. Asbestos Exposure 
Asbestos exposure leads to asbestosis and to the development of pleural plaques; it also increases 
the risk of mesothelioma and lung cancer. Asbestosis and pleural plaques exhibit unpredictable but 
progressive development, and there are no markers routinely available for assessing their prognosis. 
Asbestos  exposure  induces  the  generation  of  reactive  oxygen  species,  and  8-IsoP  is  involved  in 
experimental asbestos related lung toxicity. This oxidative stress marker was measured in EBC in 
former asbestos workers. The mean level of 8-IsoP in asbestos-exposed subjects reached the level of 
69.5 ± 6.6 pg/mL  and was higher compared with  the control group, where  the concentration was Int. J. Mol. Sci. 2010, 11                      
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47.0 ± 7.8 pg/mL. The results presented support the hypothesis that oxidative stress due to asbestos is 
the  main  cause  of  increased  8-IsoP  in  EBC.  Measurement  of  8-IsoP  in  EBC  is  thus  a  promising 
non-invasive means for assessing the activity of asbestos-induced diseases [16]. Another study, with 
the aim of assessing oxidative stress and lung inflammation in vivo by measuring 8-IsoP in exhaled 
breath condensate from humans with asbestosis, showed that in asbestos-related disorders, markers of 
inflammation and oxidative stress were significantly elevated in subjects with asbestosis compared 
with healthy individuals but not in pleural diseases [44]. 
2.1.3. Asthma 
8-IsoPGF2α  is  detectable  in  the  exhaled  breath  condensates  of  children  with  asthma  (asthmatic 
airways are characterized by enhanced oxidative stress, which can therefore be studied by measuring 
8-IsoP) and may be used as a non-invasive measurement of oxidative stress in childhood asthma. 
Measurements  of  8-IsoP  concentrations  in  EBC  and  urine  of  children  with  problematic  and 
well-controlled  asthma  showed  that  8-IsoP  in  EBC  was  significantly  elevated  in  children  with 
problematic  asthma  [33]:  8-IsoP  levels  measured  in  urine,  however,  did  not  correlate  with  those 
measured in EBC [45]. The persistence of high levels of 8-IsoP despite the inhalation of steroids 
suggests that other treatments such as anti-oxidants might be beneficial. 
Lung oxidative stress is increased in children who are in a stable condition with asthma. 8-IsoP was 
detectable in the EBC of healthy children (mean, 34.2 ± 4.5 pg/mL), but elevated levels were found in 
both steroid-naive asthmatic children (mean, 56.4 ± 7.7 pg/mL) and steroid-treated asthmatic children 
(mean, 47.2 ± 2.3 pg/mL) [31]. However, EBC analysis cannot provide any information on the cellular 
origin of mediators. To ascertain the cellular source of 8-IsoP and PGE2 in EBC, invasive studies, such 
as  bronchial  biopsies,  are  required.  In  view  of  the  fact  that  8-IsoP  is  produced  by  the  free 
radical-induced peroxidation of arachidonic acid on plasma membrane phospholipids, all the cells in 
the airways may release this eicosanoid. 
2.1.4. Chronic and Acute Exposures 
Chronic exposures are associated with airway acidity, whereas acute exposures are more closely 
associated  with  oxidative  stress.  Thus,  the  collection  of  EBC  may  contribute  to  predicting  the 
pathological state of the airways of workers exposed to acute and chronic factors. Grain workers report 
adverse respiratory symptoms as a result of exposure to grain dust and endotoxins. Studies have shown 
that biomarkers in exhaled breath condensate (EBC) vary with the severity of airway inflammation [26]. 
2.1.5. Chronic Obstructive Pulmonary Disease—COPD 
8-IsoPs  levels  were  significantly  elevated  in  the  EBC  of  patients  with  chronic  obstructive 
pulmonary  disease  COPD  (mean  18.1 ± 2.0  vs.  5.6 ± 0.7  pg/mL),  irrespective  of  lung  function 
impairment.  Therefore,  EBC  8-isoPGF2α  levels  may  reflect  the  extension  of  lung  emphysema  in  
COPD patients [46].  Int. J. Mol. Sci. 2010, 11                      
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2.1.6. Idiopathic Pulmonary Fibrosis 
8-IsoPGF2α  has  been  observed  to  increase  in  the  EBC  of  patients  with  idiopathic  pulmonary  
fibrosis [15]. 
2.1.7. Oxidative Stress in Smokers 
The collection of EBC could be useful in the assessment of airway oxidative stress in smokers. 
However,  it  was  found  that  levels  of  8-isoPGF2α  and  hydrogen  peroxide  cannot  be  reproducibly 
assessed in exhaled breath condensate from healthy smokers because of their low concentration and/or 
the  lack  of  sensitivity  of  the  available  assays.  It  was  not  possible  to  calculate  the  within-subject 
variation in a reliable manner since only three of the 12 smokers exhibited detectable 8-isoPGF2α 
concentrations (mean 4.6 pg/mL; range 3.9–7.7 pg/mL ) [47]. 
2.1.8. Pneumoconioses 
Increased 8-isoPGF2α in the EBC was found in patients with pneumoconioses [48]. 
2.1.9. Sarcoidosis 
Elevated  concentrations  of  8-isoPGF2α  have  been  reported  in  BAL  fluid  and  exhaled  breath 
condensate  (EBC)  in  sarcoidosis.  Higher  concentrations  of  8-isoPGF2α  in  EBC  of  patients  with 
sarcoidosis were noted, whereas a significant decrease was observed only in patients who received 
treatment,  but  not  in  those  with  spontaneous  remissions.  Low  initial  8-isoPGF2α  is  a  positive 
prognostic  factor.  A  decrease  of  8-isoPGF2α  in  treated  patients  reflects  a  non-specific  effect  of 
treatment and is not related to a mere regression of the disease [49]. 
2.1.10. Silicosis 
Silicosis is a chronic occupational disease caused by the inhalation of crystalline silica particles for 
prolonged periods, which produces inflammation and tissue destruction followed by remodeling of the 
extracellular matrix. 8-isoPGF2α has been seen to increase in bronchoalveolar lavage in subjects with 
interstitial  lung  diseases,  such  as  cryptogenic  fibrosing  alveolitis,  and  recently  in  EBC  of  such 
patients [15,35]. 
In silicosis, increased levels of 8-isoPGF2α together with leukotriene D4 were found in exhaled 
breath condensate (73.6 ± 9.9 pg/mL) [50]. 
2.1.11. Systemic Sclerosis 
Systemic sclerosis is a systemic connective tissue disease. Increased level of 8-isoprostane in EBC
 
from patients with systemic sclerosis reflect the inflammatory pattern involving
 oxidative stress [51]. 
2.2. Standardization of EBC Measurement 
Guidelines  were  published  by  the  American  Thoracic  Society  (ATS)  for  EBC  Measurement  in  
2005 [52], but the lack of standardization of EBC analysis is currently the principal limitation of this Int. J. Mol. Sci. 2010, 11                      
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technique making it difficult to compare data obtained in different laboratories. Reference analytical 
techniques are required to provide definitive evidence for the presence of several biomolecules in EBC 
and  an  accurate  assessment  of  their  concentrations  in  this  biological  fluid.  Moreover,  several 
methodological issues need to be addressed before this technique can be considered in the clinical 
management of patients. 
3. Composition of EBC Samples 
Exhaled breath condensate is considered now as a promising source of lung disease biomarkers. It 
is quite a simple matrix in which biomarkers may be identified, in a way equivalent to blood, sweat, 
tears, urine and saliva. Figure 6 illustrates the formation of EBC. Exhaled air consists basically of 
water vapor and substances that reflect the functional status of the lung and other tissues. 
EBC usually consists of more than 99.9% of distilled water that condenses from the gas phase out 
of the nearly water-saturated exhalate (substantially diluting the aerosolized airway lining fluid). This 
phase contains:  
•  droplets  of  variable  size  (during  normal  tidal  breathing,  levels  of  aerosol  particles  range 
between 0.1 and 4 particles/cm
3, the mean particle diameter is <0.3 µm [53–55]), aerosolized 
from the airway lining fluid—such particles, presumably reflecting the fluid itself, emanate 
from the mouth or endotracheal tube in exhaled air [56]; they serve as the only explanation for 
the presence of clearly non-volatile constituents in EBC such as sodium ions [57]. 
•  water-soluble  volatiles  compounds  (exhaled  and  absorbed  in  the  condensing  breath)  and 
non-volatile constituents (compounds mostly derived from the airway lining fluid particles). 
There are several mechanisms by which volatile and nonvolatile substances pass from the lungs to 
the EBC, but first and foremost it is the turbulence developing as air passes that generates sufficient 
energy for molecules to break away from the airway walls. 
Figure 6. Formation of an exhaled breath sample. (a) Respiratory droplets are released 
from the surfaces of the airways/air spaces. Much greater quantities of water are released 
as  vapor  (dotted  arrows);  (b)  when  the  respiratory  droplets  reach  the  condenser,  they 
become diluted by large volumes of water vapor that are deposited as large droplets on the 
walls of the condenser. 
 Int. J. Mol. Sci. 2010, 11                      
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Then, the concentration of some of the most frequently analyzed substances in EBC (like hydrogen 
peroxide)  depends on the  airflow  generated during  the  procedure, while that  of other components 
(8-IsoP and ethanol) is independent of airflow. 
Another mechanism affecting the collection of EBC is the Venturi effect, produced with the opening 
and closing of the bronchi and alveoli, although little is known of its implications [58]. 
There  is  currently  no  standard  invasive  or  non-invasive  method  of  determining  absolute 
concentrations  of  airway  lining  fluid  non-volatile  constituents  with  which  EBC  can  be  readily 
compared. However invasively collecting samples from healthy lungs additionally limits knowledge of 
normal  airway  fluid  components,  and  normal  variability.  Invasiveness  or  discomfort  of  collection 
drastically limits the ability to study airway components. These issues underlie the attractiveness of 
EBC as a research and clinical tool.  
4. EBC Sample Collection  
All the volatile and nonvolatile substances present in EBC can be analyzed by condensing exhaled 
air by passing it through a cooling unit. As mentioned already, interest in EBC lies first and foremost 
in its simplicity of collection in nearly any setting. Entirely non-invasive, it usually takes 5–10 min in 
adults and up to 15–20 min in children to obtain 1–3 mL of condensate, which is a sufficient sample 
for multiple biomarkers analysis. Only a few studies have used very a short (3 min) or a prolonged 
(60 min) collection time. The mean volume of air inhaled over 15 minutes was 119 ± 25 L, (95% 
confidence interval, 112–125 L). The mean volume of condensate in exhaled air over a period of 
15 minutes was 1.8 ± 0.5 mL (95% confidence interval, 1.5–2 mL) and the coefficient of variation was 
29%. The direct relation between the volume of EBC collected and the volume of air inhaled for each 
individual  is  expressed  by  the  following  equation:  volume  of  EBC  (mL)  =  0.013 × volume  of  
air (L) + 0.255 [59]. Direct comparison of different collection times has only been studied with respect 
to  pH:  changes  in  collection  time  did  not  show  any  effect.  No  difference  could  be  found  in  the 
concentrations of 8-isoPGF2α between studies using 10, 15 or 20 min for EBC sampling [52]. 
The amount of condensate generated per exhalation varies among individuals. Minute ventilation 
remains the major determinant of the amount of condensate over time, and it does not have any effects 
on levels of measured substances [60]. 
There  are  several  different  ways  of  obtaining  EBC  sample—they  are  optimized  to  collect  the 
mediator of interest. Patients are asked to breathe tidally through the mouthpiece, which is connected 
to a collecting device cooled to 0 °C. Breathing air through a cooling system results in condensation, 
thereby rendering collection of exhaled breath possible in liquid form. Condensation of exhaled breath 
can be achieved simply by cooling the tubing through which the patient is exhaling.  
The condensing chambers used to date have been made from glass, polystyrene or polypropylene. 
The composition of the EBC may be altered by the adhesive properties of the material from which the 
container is made. When analysis of bioactive lipids is planned, polypropylene containers should be 
considered  for  collection  to  avoid  the  problem  of  adsorption  that  can  occur  with  polystyrene 
containers. There is still no knowledge about whether different surfaces or coating materials interact 
with  different  EBC  components.  In  one  particular  study,  glass,  Teflon,  silicone,  aluminum  and 
polypropylene were tested for the recovery of 8-IsoP in EBC [61].  Int. J. Mol. Sci. 2010, 11                      
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Exhaled air is readily cooled with wet ice as well as with dry ice or liquid nitrogen.  
The dead space volume in the collection systems is compared to direct sampling of the mouth or 
nasal  passages.  In  general,  the equipment  dead space  should  be  kept as  low as  possible to  avoid 
significant re-breathing of carbon dioxide and also to minimize condensation or deposition of aerosol 
on the mask’s inner surface. 
Successful collection has been reported with a variety of devices of different designs. The most 
widely used designs include immersion of Teflon-lined tubing in an ice-filled bucket, and a specially 
designed double-wall glass condenser system [54]. 
Several appliances are commercially available for the collection of EBC samples. They are briefly 
characterized in Table 1. 
Table 1. Commercially available exhaled breath condensate collection systems. 
EBC Collection 
System 
(Manufacturer) 
Advantages  Disadvantages  References 
ECoScreen I and 
ECoScreen II 
(Viasys, U.S., 
Europe) 
The most commonly applied EBC 
collection system. More often used 
in European countries. There is an 
optional package for determining 
the total exhaled volume. 
Not readily portable. Cleaning 
between patients may need to be 
extensive to abide by standard 
respiratory care practices. No 
way of controlling condensation 
temperature (Eco1). 
[13,29,44,49,62–63] 
 
Rtube 
(Respiratory 
Research, U.S.) 
More total EBC collections than 
other systems. Multiple collections 
can be performed concurrently. 
Most commonly applied in North 
American centers. No cleaning 
between patients is necessary. 
Portable. Can be prepared for use 
in a standard freezer. 
Choice and maintenance of set 
condensing temperature requires 
an optional cooling unit, 
otherwise the condensation 
temperature is chosen by cooling 
the sleeve preparation 
temperature and rises during 
collection. 
[64–66] 
Anacon 
(Biostec, Valencia, 
Spain) 
Temperature of collection can be 
controlled. Designed for use on 
ventilated patients 
Only a few publications are 
available. 
[67,68] 
TurboDeccs 
(ItalChill, Parma, 
Italy) 
Has both non-disposable and 
disposable portions. Controllable 
collection temperature. Moderately 
portable. Readily cleanable 
because components are 
disposable. 
Very few publications exist. 
Only one collection at a time is 
possible. 
[69] 
Polish Patent 
Constant maximum contact 
between the test-tube and the 
cooling agent. Possibility of 
inserting different sizes of test 
tubes. 
Dismantling and cleaning after 
use is necessary. 
[70] Int. J. Mol. Sci. 2010, 11                      
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4.1. EcoScreen 
The ECoScreen device (Erich Jaeger GmbH, Höchberg, Germany)—an illustration and diagram of 
which is presented in Figure 7—is an electrical refrigerated system. It has an extendable arm that 
allows the subject to sit upright on a chair and exhale into a cooled chamber. The condenser maintains 
a cold temperature (−20 °C) throughout the 5- to 15-minute collection period. As it is the size of a 
desktop personal computer, however, it is not easily portable. It uses a saliva trap consisting of a hole 
near the mouthpiece that reportedly keeps the collected fluid amylase-free. Pooling of the condensate 
requires  either  sufficient  sampling  time  to  overcome  surface  tension  issues  or  centrifuging  of  the 
collection chamber. 
Figure 7. Illustration and diagram of the ECoScreen device for collecting EBC. 
 
 
The  ECoScreen  device  has  important  features:  It  is  commercially  available,  widely  used  and 
prevents contamination of EBC with saliva. However, this device may have limitations as exhaled 
breath condenses on a Teflon coated surface that is repeatedly used. The ECoScreen device is not 
portable, and the amount of sample is strictly connected with the breathing time. Recently, it was 
reported  that  NOx  measurements  might  be  confounded  by  the  device  and  represent  (partly) 
contamination with NOx originating from the device itself [71].  
4.2. Rtube 
The  RTube™  breath  condensate  collection  device  shown  in  Figure  8  is  also  called  a  Portable 
Collection Device and designed for ease of use by the unsupervised patient in the home, workplace, 
laboratory, hospital or clinic. Int. J. Mol. Sci. 2010, 11                      
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Figure 8. Illustration and diagram of the Rtube device for collecting EBC. 
 
This device uses an exhalation valve that also serves as a syringe-style plunger to pool fluid off the 
condenser  walls,  allowing  for  collection  times  of  as  little  as  one  minute.  Cooling  is  achieved  by 
placing an aluminum cooling sleeve over the disposable polypropylene condensation chamber, which 
can also serve as the sample storage container. The temperature of the cooling sleeve can be chosen by 
the investigator. Single-use design eliminates any possibility of infectious cross-contamination. The 
device inherently prevents salivary contamination with large a “T” section, in which saliva separates 
from the exhaled breath, and no evidence of salivary amylase in the condensed fluid has been reported. 
An attachable microbial filter (0.3 µm) is provided to prevent transmission of infectious particles. 
Fully self-contained and disposable, this handheld device is therefore clean and ready for use at any 
time. No cleaning is necessary. As the subject breathes normally into the device, the RTube gathers 
breath condensate in a transportable cartridge that is easily shipped in the mail for centralized sample 
analysis.  The  simplicity  and  environmental  flexibility  of  this  collector  offers  potential  for  rapid 
development of clinical diagnostics utilizing EBC. 
Measurements in EBC samples collected by RTube and ECoScreen are repeatable and reproducible 
in healthy controls, COPD and asthma patients, and subjects with a common cold [72]. 
However,  some  authors  announced  that  EBC  collection  devices  influence  the  efficiency  of 
collection but can also introduce errors in the measurement of total protein levels in EBC.  
4.3. Other Systems for EBC Collection 
A unique home-made system for EBC collection has been presented in the literature recently [73]. 
Respiratory  droplets  can  be  collected  by  procedures  other  than  condensation  on  cold  surfaces,  
e.g.,  filtration,  impaction,  and  electrostatic  precipitation  on  devices  at  body  temperature.  After 
collection the solutes can be washed off with small volumes of water. These alternative techniques 
may reduce the amount of unwanted water vapor and volatile buffers, such as ammonium, but may not 
be suitable for thermally labile or volatile mediators [74]. Int. J. Mol. Sci. 2010, 11                      
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The  Department  of  Instrument  Development  Engineering  and  Evaluation  of  the  Maastricht 
University Medical Center has published a new design of an EBC collection system for use in young 
children [75].  Figure 9 shows a  schematic representation of this closed glass condenser. In  short, 
children breathe tidally for 10 minutes through a mask connected to the two-way non-rebreathing 
valve. EBC is collected using a cooled double-jacketed glass condenser that is connected to the valve 
via  a  tube.  The  two-way  valve  and  tubing  serve  as  a  trap  to  minimize  salivary  contamination. 
Circulating ice water cools the condenser to 0 °C. During this procedure small droplets of breath 
condensate  are  formed  which  is  collected  in  a  tube;  while  this  is  happening,  children  can  watch 
cartoons. Exhaled breath that does not directly condense in the condenser is collected in an inert bag 
connected to the condenser. To prevent the exhaled breath from condensing in the bag, it is placed in a 
heated box (37 °C). When the child finishes the procedure, the exhaled breath that is temporarily 
collected in the inert bag is conducted through the condenser (recirculation) to increase the amount of 
condensate. After collection, EBC is rapidly frozen at −80 °C using dry ice, then stored at −80 °C  
until analysis. 
Figure 9. Schematic representation of the glass closed condenser. Inclined glass condenser 
with  a  moveable  plunger;  swan-neck tubing  (saliva  trap)  and  two-way  non-rebreathing 
valve, connected to a face mask with separated nose and mouth cavity, entrance of inspired 
room air; cooling unit; sample vial to collect EBC; ventilator system for recirculation of 
non-condensed exhaled breath; heated (at 37 °C); inert Tedlar™ gas sample bag to collect 
the residual non-condensed exhaled breath.  
 
 
A new device has been patented at the Medical University of Łódź, Poland (see Figure 10). A tube 
for sample collection is placed in an isolated tensile filled with cooling liquid (dry ice, liquefied air, ice 
or water). If necessary, a bigger test-tube can be inserted, depending on the further analysis of the 
sample collected. Through the hole in the cover, a pipe with mouthpiece is placed inside the device. 
The lower part of the pipe is extended, which prevents the condensate from escaping with the air flow. 
The pipe also has a saliva catcher to prevent contamination of the sample. Holes in the cover enable 
sublimation or evaporation of cooling agent. An elevator maintains the test-tube in maximum contact 
with the cooling agent. Water vapor, particles and bronchial secretions condense and freeze on the 
walls of test-tube. Dried air (due to the pressure obtained from the breath of the test objects) leaves the Int. J. Mol. Sci. 2010, 11                      
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device through the holes in the cover or is passed to the respiratory system. However, after every use, 
this device  must be dismantled and  cleaned. This device for collecting exhaled breath condensate 
enables samples to be collected even from unconscious patients. 
Figure 10. Diagram of the device constructed at the Medical University of Łódź. 
 
There  is  currently  no  standard  invasive  or  non-invasive  method  of  determining  absolute 
concentrations of the non-volatile, constituents of the airway lining with which EBC can be readily 
compared.  However,  the  invasive  collection  of  samples  from  healthy  lungs  additionally  limits 
knowledge of normal airway fluid components, and normal variability. Invasiveness or discomfort of 
collection  drastically  limits  ability  to  study  airway  components.  These  issues  underlie  the 
attractiveness of EBC as a research and clinical tool. There is a clear and urgent need for standardized 
methods of EBC collection and storage for certain individual biomarkers. 
5. Salivary Contamination of EBC 
In oral EBC collection, depending in part on the EBC collection equipment, gross or microscopic 
salivary contamination of EBC may and sometimes does occur [76]. Measures of salivary amylase are 
often used to test for the presence of salivary contamination. Most investigators find that no amylase is 
identified in the great majority of samples. Higher sensitivity assays tend to report the presence of 
measurable amylase in a subset of samples [76]. Saliva is the source of less than 10% of respiratory 
droplets  [77].  The  ratios  among  various  non-volatile  compounds  in  EBC  has  been  found  to  be 
substantially different from the ratio of compounds in saliva, suggesting a dominant (but not entire) 
lower airway source of EBC constituents [77]. If care is taken to exclude saliva from EBC samples, 
amylase can be detected in only a small portion of samples with levels approximately 10000 times 
lower than those in saliva [78]. In addition, amylase measurements are not specific to salivary amylase, 
and amylase can also be found in the lungs, so positive results of the test do not necessarily mean 
salivary contamination. Some solutes measured in EBC such as eicosanoids have been examined as 
markers of salivary contamination as well [79–80]. Even when collected free of saliva contamination 
the majority of proteins present in EBC were also found in saliva, suggesting that these proteins are 
present in both compartments, e.g., saliva and secretions of the lower airspaces. The quantification and Int. J. Mol. Sci. 2010, 11                      
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identification  of  specific  proteins  in  the  various  compartments  is  warranted  in  future  studies  to 
determine the practical value of EBC. 
6. Storage of EBC Samples 
Because  on-line  measurements are  not available  for  most  biomarkers present  in  EBC  with  the 
exception of a few assays including those for pH and H2O2, EBC samples are usually stored before 
final measurements. EBC samples should be immediately frozen after collection and stored at −70 °C 
until  biomarker  determination  is  performed.  Another  case  to  consider  is  the  number  of  target 
compounds. Samples of EBC should be divided into parts and stored separately. At present, very little 
is known about the reproducibility and stability of biomarkers during long term storage [81]. However, 
it  is  well  known  that  multiple  frosting-defrosting  cycles  could  destroy  some  biomarkers  like 
prostaglandins  [52].  Even  when  stored  under  these  conditions,  some  analytes  are  not  stable  after 
long-term storage. For example, the concentration of H2O2 is known to decrease causing detectable 
change in its level after a few weeks at −20 °C [82,83]. Cysteinyl-leukotrienes (cys-LTs) are also 
unstable compounds in most biological fluids, although data on their stability in EBC is not well 
documented. Isoprostanes stability has been studied by several authors [25,46]. On the other hand pH 
has been reported to be stable up to two years of storage [82]. 
Also, other types of samples can be successfully stored over long periods of time. Samples of blood 
plasma  immediately  frozen  in  liquid  nitrogen  and  stored  at  −80  °C  exhibit  no  auto-oxidation  
for  up  to  eight  months.  Similar  precalculations  have  to  be  considered  when  handling  the  solid  
tissue samples [2]. 
7. Sample Preparation 
Since the majority of the sample consists of condensed water vapor, most biomarkers exist in EBC 
at very low concentrations. Sample preconcentration is necessary to improve the limits of detection 
(LODs) of any analytical method. Isoprostanes can be preconcentrated from EBC samples by either 
lyophilisation or adsorption on sorbent traps (SPE). 
7.1. Lyophilization 
Lyophilization  as  an  exceptional  technique  for  concentrating  non-volatile  (or  semi-volatile) 
substances dissolved in water. Since this technique is extremely suitable for heat-labile substances, it is 
fairly  often used as the preconcentration stage for  8-isoprostane contained in EBC. During freeze 
drying of the EBC sample, no temperature stress on the labile markers of oxidative stress occurs, 
which could lead to the preference of lyophilization over other potential pre-treatment techniques. 
Lyophilization is based on dehydrating a delicate sample that would otherwise be damaged by the 
drying process. By regulating the temperature and pressure of the sample, freeze-drying brings the 
sample system around the triple point of a typical phase diagram, thereby avoiding the liquid–gas 
transition seen in ordinary drying. After lyophilization is complete, all free water is removed and the 
solute remains. This solute can then be reconstituted in a solution of choice. However, in contrast to 
this  temperature  advantage,  there  is  also  no  separation  capability  from  the  other  non-volatile 
substances  present  in  EBC,  which  are  concentrated  as  well.  This  could  result  in  a  deteriorated Int. J. Mol. Sci. 2010, 11                      
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ionization during the mass spectrometric measurement or possibly elevated noise even in preceding 
liquid chromatography step. This is apparently, caused by the presence of a high amount of substances 
including salts. This fact could be negatively reflected in higher values of LOD and LOQ as well as 
poorer method accuracy in low (picogram) concentrations compared to other potential pre-treatment 
methods. On the other hand, the EBC matrix is composed mainly of water, whereas the content of 
non-volatile substances and salts is relatively low compared to other body fluids (urine, blood plasma, 
cerebrospinal fluid). 
So far, lyophilization has been used by many research groups evaluating EBC biomarkers [84–87].  
A 1mL EBC sample lyophilized and resuspended into 50 µL of mobile phase used for further analysis 
gives a 20-fold concentration. Reconstituted volumes can be applied to multiple immunoassays [84] or 
HPLC determination [85]. 
7.2. Solid Phase Extraction 
Solid phase extraction (SPE) is a technique designed for rapid, selective sample preparation and 
purification  prior  to  chromatographic  analysis.  Using  liquid  chromatography  principles  to  control 
selectivity,  SPE  provides  the  sample  clean-up,  recovery,  and  concentration  necessary  for  accurate 
quantitative  analysis.  Over  the  last  twenty  years,  SPE  has  become  the  most  powerful  technique 
available  for  rapid  and  selective  sample  preparation  and  preconcentration.  The  concentration  of 
analytes for increased sensitivity is the main aim of applying SPE to EBC. General guidelines for 
choosing  the  appropriate  SPE  tube  size,  bed  weight  and  sorbent  type  are  available.  Nevertheless, 
optimal method  parameters  should be  determined during method optimization.  Providing the  right 
adsorbent is chosen, the extraction process can be very efficient, e.g., >99%. Although, solid phase 
extraction is an extremely efficient method for isolating and concentrating solutes from relatively large 
volumes of liquid, this technique can be very effective, even when the solutes are present at extremely 
dilute concentrations (e.g., ppb) and in small sample volumes. Generally, 3 mL SPE tubes are the most 
common size. However, smaller tube volumes (1 mL), which contain smaller bed weights, allow for 
reduced elution volumes, which can be beneficial for sensitive analyses, as in the case of biomarker 
determination  in  EBC  samples.  Materials  extracted  by  SPE  can  be  used  for  subsequent 
chromatographic  separation,  spectroscopic  examination  or  biological  assessment.  For  isoprostane 
extraction and concentration from EBC, which contains large amounts of water, the reversed phase 
mode is usually applicable.  
In order to obtain good results using SPE, there are basic steps to perform:  
•  Sample Pretreatment for interferent-laden samples (e.g., biological fluids)—dilute samples 1:1 
with  buffer.  pH  manipulation  may  be  important  in  the  case  of  ionizable  compounds.  A 
compound’s ionization state can drastically change its retention and elution characteristics on a 
given SPE sorbent. When an analyte is in its neutral form, it becomes more hydrophobic and 
retention strengthens under reversed-phase conditions. Adjusting the sample pH to 2 pH units 
above  or  below  the  compound’s  pKa  (depending  on  the  functional  group)  will  effectively 
neutralize the compound. Non-polar solvents  (including methanol  and isopropanol) prevent 
interaction between the compound and sorbent functional groups. To avoid clogging, it may be 
necessary to centrifuge, or pre-filter the sample prior to introducing it to the SPE phase. Int. J. Mol. Sci. 2010, 11                      
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•  Conditioning/Equilibration wets or activates the bonded phases to ensure consistent interaction 
between  the  analyte  and  the  sorbent  functional  groups.  Reversed-phase  sorbents  are  often 
conditioned  with  1–2  tube  volumes  of  a  water-miscible  solvent  such  as  methanol  or 
acetonitrile. Equilibration introduces a solution similar to the sample load in terms of solvent 
strength and pH in order to maximize retention. 1–2 tube volumes of buffer (used in sample 
pre-treatment) or water are good choices for reversed-phase equilibration.  
•  Sample Loading must be done at a consistent and reduced flow rate of ~1–2 drops per second 
to ensure optimal retention.  
•  Washing  of  sample  interferences  that  are  often  co-retained  with  target  compounds  during 
sample loading. A washing step is necessary to elute interferences without prematurely eluting 
target  compounds.  5–20%  methanol  in  water  or  sample  pre-treatment  buffer  is  typical  for 
washing solvents. 
•  Elution  can  be  performed  with  an  organic  solvent  or  solvent  combination  of  sufficient 
non-polar  character  in  order  to  prevent  hydrophobic  interactions  between  the  analyte  and 
sorbent  functional  groups.  Example  elution  solvents  are  1–2  volumes  of  methanol  or 
acetonitrile.  pH  manipulation  during  elution  can  often  improve  recovery  in  the  case  of 
ionizable compounds. In their ionic form, basic and acidic compounds become more polar, 
attenuating  reversed-phase  interaction,  so  weaker  elution  solvents  and/or  reduced  elution 
volumes can be used.  
•  Eluate  Post-treatment  is  often  necessary  in,  for  example  evaporation  to  dryness  and 
reconstitution  of  SPE  eluate  in  the  mobile  phase  prior  to  LC  analysis.  GC  analysis  often 
requires  further  SPE  eluate  concentration,  possible  matrix  exchange  with  a  more  volatile 
solvent and/or derivatization. 
Table 2. Examples of sample preparation procedures for EBC samples with different final 
analysis techniques. 
Analytical 
Technique 
Sample Preparation  LOD  Ref. 
RIA 
standard curves obtained using phosphate buffer 0.025 mol/L,  
pH 7.5, more similar to EBC matrix 
10 pg/mL  [91] 
samples stored at −80 °C before analysis  10 pg/mL  [36] 
EIA 
after sampling no further preparation of the sample is necessary, 
samples stored at −80 °C before analysis 
4–5 g/mL 
[25,46,63,
92–95] 
SPE of pooleed sample (35.5 mL), HPLC purification  10 pg/mL  [90] 
LC-MS/MS 
samples pretreated with 50 µL of immunoaffinity sorbent for 60 min  1 pg/mL  [17] 
after collection sample spiked with 8-isoPGF2α-d4, stored at −80 °C, 
lyophilization, redissolved in 50 µL of water/methanol (1:1) 
8 pg/mL  [85] 
sample spiked with 8-isoPGF2α-d4, pretreated with 50 µL of 
immunoaffinity sorbent for 60min at 20 °C, centrifuged (3000 rpm 
for 5 min), immunoaffinity sorbent flushed twice with water, elution 
with methanol, methanol evaporated, redissolved in 50 µL of mobile 
phase 
1 pg/mL  [14] 
LC-MS  immunoaffinity separation  1 pg/mL  [16] Int. J. Mol. Sci. 2010, 11                      
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Several authors have reported the application of SPE for IsoPs preconcentration from EBC samples. 
Generally,  two  types  of  SPE  sorbents  are  applied:  RP-18  sorbents  [88–90]  and  immunoaffinity 
sorbents  [14,17,89].  In  table  2  are  presented  procedures  most  common  used  for  EBC  sample 
preparation. 
8. Determination of Isoprostanes in EBC Samples 
A variety of analytical techniques are involved in the final step, which enables identification and 
quantitative analysis of the compounds present in exhaled breath condensates, from metabolic end 
products to proteins, to a diversity of cytokines and chemokines. Most of the mediators found in EBC 
samples are in the lower range of detection of the techniques currently available, where the intra- and 
inter-assay  variability  of  methods  is  large.  An  option  to  overcome  this  problem  is  sample 
preconcentration  by  SPE,  lyophilization  and  vacuum  evaporation,  as  discussed  earlier.  Volatile, 
semi-volatile and unstable substances are very likely to be lost during freeze-drying.  
Figure 11. The analytical techniques most commonly used to determine isoprostanes in 
exhaled breath condensates. 
 
Determination  of  IsoPs  in  exhaled  breath  condensates  is  based  on  immunoanalytical  and 
chromatographic  techniques  (Figure  11).  Radioimmunoassay  (RIA)  is  one  of  the  most  efficient, 
convenient and accurate techniques for the detection of small amounts of analytes in fluids, because 
radioactivity  is fairly free of matrix  interferences and can be measured  in  small  amounts.  RIA is 
cost-effective,  specific,  sensitive  and  does  not  require  sample  preparation.  Because  dilution  of 
respiratory droplets by water vapor may explain part of the variation in concentrations of non-volatile 
compounds in EBC, results can be presented as a change in the ratio the target analyte concentration to 
the concentration of another eicosanoids [91]. RIA or enzyme immunoassay (EIA) techniques offer 
ease of performance, the possibility of automation and low cost of analysis. In most published studies, 
IsoPs  have  been  measured  using  commercially  available  enzyme  immunoassays  [25,46,63,92–95]. 
However, the available ELISA kits were originally validated for matrices other than EBC, such as 
urine, plasma or serum. Quantification by ELISA-kits could be influenced by the matrix in which the 
analytes are dissolved. In view of the extremely high dilution of the epithelial lining fluid in EBC (and 
the resulting low concentrations), EBC can be considered to contain only little matrix compared to 
other highly concentrated and protein-rich matrices such as plasma or urine. EBC is characterized by Int. J. Mol. Sci. 2010, 11                      
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low concentrations of proteins and amino acids, so that matrix influences should be minimal, both for 
ELISA and more specific analytical techniques, e.g., gas chromatography mass spectrometry (GC-MS) 
or  liquid  chromatography  mass  spectrometry  (LC-MS),  suggesting  good  comparability  of  both 
detection  techniques.  A  comprehensive  comparison  of  two  unrelated  analytical  techniques  was 
performed in order to quantify the three most frequently analyzed eicosanoids in EBC [96]. The results 
obtained in this study show that ELISA overestimates the eicosanoids in EBC. On the other hand, a 
method  developed  for  determining  of  8-iso-PGF2α  in  EBC  from  asthmatics,  shows  acceptable
 
reproducibility of EIA compared to GC/NICI-MS, even if the latter
 method had higher accuracy [45]. 
Therefore,  quantification  by  immunoassays  has  to  be  validated  by  GC-MS/MS  or  LC-MS  to 
provide definitive evidence for accurate quantitative biomarkers results in EBC.  
8.1. Gas Chromatography with Mass Spectrometry and Tandem Mass Spectrometry Detection 
The presence of 8-iso-PGF2α was confirmed for the first time in EBC using stable isotope dilution 
method in conjunction with GC-MS [97]. Since that time, analysis of EBC has hardly ever been done 
by GC-MS and GC-MS/MS due to derivatization of analytes. It is more often applied to samples like 
urine,  plasma  or  tissues,  where  the  complicated  sample  preparation  usually  requires  at  least  one 
extraction step and one purification step. Derivatizing the carboxylic acid, common to all eicosanoids, 
to the pentafluorobenzyl  ester  is the key  to its sensitivity. The reagents  most commonly used for 
derivatization are N,N-Diisopropylethylamine (DIPEA) with Pentafluorobenzyl bromide (PFBBr) [98] 
and Bis(Trimethylsilyl)-Trifluoroacetamide (BSTFA) with Dimethylformamide (DMF) [20]. GC-MS 
and GC-MS/MS techniques are sensitive to quantitate a single F2-isoprostane isomer in a 1 mL sample 
but not specific enough to separate F2-isoprostane isomers from each other. A method was found 
where  prostaglandins,  8-isoPGF2α  and  3-nitrotyrosine  were  detected  in  EBC  from  asthmatics  and 
healthy non-smokers. In all asthmatics and controls, prostaglandins, 8-isoprostane, and 3-nitrotyrosine 
were not detectable by GC-MS or LC-MS analysis [99]. 
8.2. Liquid Chromatography with Mass Spectrometry and Tandem Mass Spectrometry Detection 
In the past decade, LC has become the practical alternative to gas chromatography. This is because 
no derivatization is needed for semi-volatile and non-volatile compounds, which are thermolabile. The 
two main ionization modes used in current commercial instruments are electrospray ionization and 
atmospheric pressure chemical ionization (APCI). Different acquisition modes are available in modern 
LC-MS/MS instruments. During qualitative determination, the full-scan mode is useful where a range 
of m/z values encompassing the analytes of interest is constantly monitored. Based on these results, 
pseudomolecular and fragmentation ions can be obtained, so molecular mass and fragments may help 
to identify analytes. On the other hand, multiple reaction monitoring (MRM mode) is in common use. 
In this mode, a specific set of precursor ions is selected and their transition from the selected precursor 
ion to a specific product ion is monitored. This reduces chemical noise leading to higher mass spectral 
sensitivity and selectivity, which is used for quantitative determination. 
Weakly acidic isoprostane isomers (pKa ~ 5) can be deprotonated to form (M-H) precursor ions in 
the electrospray ionization  source and detected in the negative ion mode. MS/MS can  be used to 
fragment the precursor ions and form specific product ions. The multiple reaction-monitoring (MRM) Int. J. Mol. Sci. 2010, 11                      
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mode is used for its extremely high degree of selectivity and the stable isotope dilution assay for its 
high precision of quantification. The scan monitoring reaction used for analyses were 353→193 for 
8-iso-PGF2α and 357→197 for [3,3’,4,4’ 
2H4] 8-iso-PGF2α. 
The application of liquid chromatography/mass spectrometry (LC-MS/MS) has a few advantages: 
Unlike to GC-MS, it does not require the two-step derivatization procedure, which means improved 
recovery,  a  shorter  sample  pre-treatment  time,  and  the  absence  of  incomplete  derivatization 
by-products. Examples of chromatographic parameters for determining IsoPs in biological samples are 
presented in Table 3. 
Tandem mass spectrometry coupled with LC offers the high sensitivity, specificity, and accuracy 
that are required for biomarkers determination in EBC. 
Table  3.  Chromatographic  parameters  in  the  analysis  of  biological  samples  for 
isoprostanes’ determination. 
Specimen  Determined Analyte  Column  Eluents  Ref. 
EBC  8-iso-PGF2α 
Hypercarb Thermo 
100 mm × 2.1 mm × 5 µm 
A: acetonitrile 
B: water (pH 11)  
isocratic elution A:B (7:3) 
flow rate 250 µL/min 
[14,17]  
EBC 
8-iso-PGF2α  
o-Tyr  
8-OHdG  
Hypercarb Thermo 100 mm 
× 2.1 mm × 5 µm 
A: aqueous solution of ammonium 
hydroxide pH 10.5 
B: methanol:acetonitrile 
60:40 (v/v) + 0.1% of ammonium 
hydroxide gradient elution 
[85] 
Urine  
Plasma 
8-iso-PGF2α 
Symmetry C8  
150 mm × 3.9 mm ×  
5 µm 
A: 0.1% acetic acid (pH 3) 
B: acetonitrile 
isocratic elution A:B (7:3) 
[8] 
Urine  8-iso-PGF2α 
YMC ODS-AQ  
50 mm × 2.0 mm × 3 µm 
A: methanol: acetonitrile 5:95( v/v) 
B: 2 mM ammonium acetate 
gradient elution 
flow rate 0.2 mL/min 
[7] 
Urine  8-iso-PGF2α 
Phenomenex 
Gemini C 18 110 Å, 
50mm × 2.0 mm × 3 µm 
A: 0.1% aqueous solution of ammonium 
hydroxide 
B: 0.1% ammonium hydroxide in 
acetonitrile 
gradient elution 
[9] 
Plasma 
8-iso-PGF2α 
8-iso-15(R)PGF2α 
11β-PGF2α 
15(R)-PGF2α 
PGF2α 
Synergi Hydro-RP 
250 mm × 2.0mm 
A: water + 0.01% acetic acid 
B: methanol 
gradient elution 
[10] 
Urine 
8-iso-PGF2α 
8-iso-15(R)-PGF2α  
8-iso-PGF2β 
PGF2α 
Hypercarb, 5 µm, 
1 mm × 150 mm, porous 
graphitic carbon column 
A: water + 0.5% aqueous solution of 
ammonium hydroxide (pH 9.5) 
B: acetonitrile:methanol 40:60(v/v) + 0.5% 
aqueous solution of ammonium hydroxide 
flow rate 50 µL/min 
gradient elution 
[6] Int. J. Mol. Sci. 2010, 11                      
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9. Trends and Future Directions 
EBC  analysis  is  expanding  on  its  promise  of  expanding  the  number  of  mediators  that  can  be 
measured to provide clinically useful methods by which to measure and monitor therapy, biochemical 
processes,  alterations  in  air  flow  (characteristics)  and  inflammatory  lung  diseases  [58].  The  main 
aspects of future research will include investigation into the mechanism of EBC formation and studies 
of its relationship with airway lining fluid; the correlation of lung function and symptoms with markers 
occurring in EBC; and reproducibility of measurements [100]. To improve the routine use of EBC, 
numerous issues must be discussed, for example, matching appropriate, sensitive and specific assays  
to  detect  biomarkers,  and  the  reference  values  for  markers  found  in  EBC  to  assist  in  diagnosis  
and treatment [101].  
Proteomics, which applies high resolution gel electrophoresis or MS to detect multiple proteins in 
biological samples, may also be a useful approach to analyse proteins in EBC. The molecules detected, 
e.g.,  ribonucleic  acid  (RNA),  deoxyribonucleic  acid  (DNA)  and  microorganisms,  contribute  to 
development  of  research  in  fields  like  microbiology  and  gene  delivery.  This  may  reveal 
disease-specific  patterns  and  may  lead  to  the  identification  of  novel  proteins  for  the  detection  of 
disease and the identification of new therapeutic targets. However, there are several technical problems 
that need to be overcome before this becomes a useful approach [54].  
Metabonomics is a recent technique that may be particularly applicable to EBC analysis. It involves 
the  detection  of  hundreds  of  thousands  of  metabolites  in  a  biological  fluid  usually  using  high 
resolution  nuclear  magnetic  resonance  spectrometry  or  liquid  chromatography/MS.  Although  less 
sensitive than ELISA and mass spectrometry, NMR requires minimal sample preparation, with a rapid 
acquisition time (10–15 min), and has a high degree of sensitivity (less than or equivalent to µmol/L 
levels). Furthermore, it is nondestructive and allows  complete detection of  observable metabolites 
(“sample metabolic fingerprint”) at a reasonable cost, screening of lung diseases, following disease 
progression, predicting responses to treatment and monitoring of response to therapy [102,103].  
10. Conclusion 
The use of exhaled breath condensate is promising because it is a simple, noninvasive technique 
that can be compared with invasive protocols for assessing lung inflammation like BAL. The low cost 
of  collection  related  with  high  reproducibility,  will  permit  real-time,  repeated  measurements  of 
pulmonary diseases. The determination of the role of EBC in diagnosis and management of individual 
patients,  an  issue  distinct  from  large  studies  of  disease  mechanisms,  awaits  further  investigation.  
It could also provide insight into the pathophysiology of inflammatory lung diseases and its potential 
usefulness for assessing the efficacy of drug therapy.  
On  the  other  hand  limitations  like  the  lack  of  a  standard  method  of  collection,  high  levels  of 
interfering substances and low concentrations of biomarkers are the main drawbacks of EBC analysis. 
Further studies need to be done on the mechanism of EBC formation. In order to introduce breath 
analysis  into  clinical  practice,  analytical  procedures  have  to  be  considerably  simplified.  For  this 
purpose, analytical devices have to be portable, be able to detect markers without delay, and be easy to 
use.  These  requirements  can  best  be  met  by  a  smart  combination  of  sampling  preparation  and  
detection techniques. Int. J. Mol. Sci. 2010, 11                      
 
4653 
Acknowledgements 
This work was financially supported by the Polish Committee for the Scientific Research (research 
project #N N404 201639) and Foundation  for Polish Science (MISTRZ programme 2009 edition). 
References 
1.  Montuschi, P.; Barnes, P.J.; Roberts, L.J., II. Isoprostanes: Markers and mediators of oxidative 
stress. FASEB J. 2004, 18, 1791–1800. 
2.  Płacik, B.; Nofer, T.W.; Wąsowicz, W. F2-isoprostanes biomarkers of lipid peroxidation: Their 
utility in evaluation of oxidative stress induced by toxic agents. Int. J. Occup. Med. Environ. 
Health 2002, 15, 19–27. 
3.  Rokach,  J.;  Khanapure,  S.P.;  Hwang,  S.W.;  Adiyaman,  M.;  Lawson,  J.A.;  FitzGerald,  G.A. 
Isoprostanes: A perspectives. Prostaglandins 1997, 54, 823–851. 
4.  Cracowski, J.L.; Durand, T.; Bessard, G. Isoprostanes as a biomarker of lipid peroxidation in 
humans: physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002, 23, 
360–366. 
5.  Comporti, M.; Signorini, C.; Arezzini, B.; Vecchio, D.; Monaco, B.; Gardi, C. F2-isoprostanes 
are not just markers of oxidative stress. Free Radical Bio. Med. 2008, 44, 247–256. 
6.  Bohnstedt,  K.C.;  Karlberg,  B.;  Wahlund,  L.-O.;  Jönhagen,  M.E.;  Basun,  H.;  Schmidt,  S. 
Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic 
carbon liquid. J. Chromatogr. B 2003, 796, 11–19. 
7.  Harman, S.M.; Liang, L.; Tsitouras, P.D.; Gucciardo, F.; Heward, C.B.; Reaven, P.D.; Ping, W.; 
Ahmed,  A.;  Cutler,  R.G.  Urinary  Excretion  of  Three  Nucleic  Acid  Oxidation  Adducts  and 
Isoprostane  F2α  Measured  by  Liquid  Chromatography-Mass  Spectrometry  in  Smokers,  
Ex-smokers, and Nonsmokers. Free Radical Bio. Med. 2003, 35, 1301–1309. 
8.  Ohashi,  N.;  Yoshikawa,  M. Rapid and  sensitive  quantification  of  8-isoprostaglandin  F  in 2a 
human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry.  
J. Chromatogr. B 2000, 746, 17–24. 
9.  Saenger,  A.K.;  Laha,  T.J.;  Edenfield,  M.J.;  Sadrzadeh,  S.M.H.  Quantification  of  urinary  
8-iso-PGF2α  using  liquid  chromatography-tandem  mass  spectrometry  and  association  with 
elevated troponin levels. Clin. Biochem. 2007, 40, 1297–1304. 
10.  Taylor, A.W.; Bruno, R.S.; Frei, B.; Traber, M.G. Benefits of prolonged gradient separation for 
high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 
15-series F2-isoprostanes. Anal. Biochem. 2006, 350, 41–51. 
11.  Greco, A.; Minghetti, L.; Puopolo, M.; Pietrobon, B.; Franzoi, M.; Chiandetti, L.; Suppiej, A. 
Plasma  levels  of  15-F2t-isoprostane  in  newborn  infants  are  affected  by  mode  of  delivery.  
Clin. Biochem. 2007, 40, 1420–1422. 
12.  Montine,  T.J.;  Markesbery,  W.R.;  Morrow,  J.D.;  Robert,  L.J.,  II.  Cerebrospinal  fluid  
F2-isoprostane levels are increased in Alzheimer’s disease. Ann. Neurol. 1998, 44, 410–413. 
13.  Shahid, S.K.; Kharitonov, S.A.; Wilson, N.M.; Bush, A.; Barnes, P.J. Exhaled 8-isoprostane in 
childhood asthma. Respir. Res. 2005, 6, 1–6. Int. J. Mol. Sci. 2010, 11                      
 
4654 
14.  Syslová, K.; Kačer, P.; Kuzma, M.; Klusáčková, P.; Fenclová, Z.; Lebedová, J.; Pelclová, D. 
Determination  of  8-iso-prostaglandin  F2  in  exhaled  breath  condensate  using  combination  of 
immunoseparation and LC–ESI-MS/MS. J. Chromatogr. B 2008, 867, 8–14. 
15.  Psathakis, K.; Mermigkis, D.; Papatheodorou, G.; Loukides, S.; Panagou, P.; Siafakas, V.P.M.; 
Bouros, D. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur. J. Clin. 
Invest. 2006, 36, 362–367. 
16.  Peclová,  D.;  Fenclová,  Z.;  Kačer,  P.;  Kuzma,  M.;  Navrátil,  T.;  Lebedová,  J.  Increased  
8-isoprostane,  a  Marker  of  Oxidative  Stress  in  Exhaled  Breath  Condensate  in  Subjects  with 
Asbestos Exposure. Ind. Health 2008, 46, 484–489. 
17.  Montuschi, P. LC-MS-MS analysis of leukotriene B4 and other eicosanoids in exhaled breath 
condensate for assessing lung inflamation. J. Chromatogr. B 2009, 877, 1272–1280. 
18.  Xie, J.; Zhang, Q.; Zhong, N.; Lai, K. BAL Fluid 8-Isoprostane Concentrations in Eosinophilic 
Bronchitis and Asthma. J. Asthma 2009, 46, 712–715. 
19.  Longini, M.; Perrone, S.; Kenanidis, A.; Vezzosi, P.; Marzocchi, B.; Petragli, F.; Centini, G.; 
Buonocore, G. Isoprostanes in amniotic fluid: A predictive marker for fetal growth restriction in 
pregnancy. Free Radical Bio. Med. 2005, 38, 1537–1541.  
20.  Morrow, J.D.; Roberts, L.J. Mass spectrometric quantification of F2-isoprostanes in biological 
fluids and tissues as measure of oxidant stress. Methods Enzymol. 1999, 300, 3–12. 
21.  Patrignani, P.; Tacconelli, S. Isoprostanes and other markers of peroxidation in atherosclerosis. 
Biomarkers 2005, 10, 24–29. 
22.  Miekisch,  W.;  Schubert,  J.K.  From  highly  sophisticated  analytical  techniques  to  life-saving 
diagnostics: Technical developments in breathanalysis. Trends Anal. Chem. 2006, 25, 665–673. 
23.  Hunt, J.; Byrns, R.E.; Ignarro, L.J.; Gaston, B. Condensed expirate nitrite as a home marker for 
acute asthma. Lancet 1995, 346, 1235–1236. 
24.  Praticò,  D.;  Lawsona,  J.A.;  Rokach,  J.;  FitzGerald,  G.A.  The  isoprostanes  in  biology  and 
medicine. Trends Endocrinol. Metab. 2001, 12, 243–247. 
25.  Samitas, K.; Chorianopoulos, D.; Vittorakis, S.; Zervas, E.; Economidou, E.; Papatheodorou, G.; 
Loukides, S.; Gaga, M. Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma 
and their relation to clinical severity. Respir. Med. 2009, 103, 750–753. 
26.  Do,  R.;  Bartlett,  K.H.;  Dimich-Ward,  H.;  Chu,  W.;  Kennedy,  S.M.  Biomarkers  of  Airway 
Acidity and Oxidative Stress in Exhaled Breath Condensate from Grain Workers. Am. J. Respir. 
Crit. Care Med. 2008, 178, 1048–1054. 
27.  Montuschi,  P.  Exhaled  breath  condensate  analysis  in  patients  with  COPD.  Clin.  Chim.  Acta 
2005, 356, 22–34. 
28.  Carpenter,  C.T.;  Price,  P.V.;  Christman,  B.W.  Exhaled  breath  condensate  isoprostanes  are 
elevated in patients with acute lung injury or ARDS. Chest 1998, 114, 1653–1659. 
29.  Petrosyan, M.; Perraki, E.; Simoes, D.; Koutsourelakis, I.; Vagiakis, E.; Roussos, C.; Gratziou, C. 
Exhaled breath markers in patients with obstructive sleep apnoea. Sleep Breath 2008, 12, 207–215. 
30.  Antczak,  A.;  Montuschi,  P.;  Kharitonov,  S.A.;  Gorski,  P.;  Barnes,  P.J.  Increased  exhaled 
cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am. J. Respir. Crit. Care 
Med. 2002, 166, 301–306. Int. J. Mol. Sci. 2010, 11                      
 
4655 
31.  Baraldi,  E.;  Ghiro,  L.;  Piovan,  V.  Increased  exhaled  8-isoprostane  in  childhood  asthma.  
Chest 2003, 124, 25–31. 
32.  Baraldi,  E.;  Carraro,  S.;  Alinovi,  R.;  Pesci,  A.;  Ghiro,  L.;  Bodini,  A.;  Piacentini,  G.;  
Zacchello,  F.;  Zanconato,  S.  Cysteinyl  leukotrienes  and  8-isoprostane  in  exhaled  breath 
condensate of children with asthma exacerbation. Thorax 2003, 58, 505–509. 
33.  Zanconato,  S.;  Carraro,  S.;  Corradi,  M.;  Alinovi,  R.;  Pasquale,  M.F.;  Piacentini,  G.;  
Zacchello,  F.;  Baraldi,  E.  Leukotrienes  and  8-isoprostane  in  exhaled  breath  condensate  of 
children with stable and unstable asthma. J. Allergy Clin. Immunol. 2004, 113, 257–263. 
34.  Biernacki, W.A.; Kharitonov, S.A.; Barnes, P.J. Increased leukotriene B4 and 8-isoprostane in 
exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003, 58, 294–298. 
35.  Montuschi,  P.;  Ciabattoni,  G.;  Paredi,  P.;  Pantelidis,  P.;  Bois,  R.M.d.;  Kharitonov,  S.A.;  
Barnes,  P.J.  8-Isoprostane  as  a  Biomarker  of  Oxidative  Stress  in  Interstitial  Lung  Diseases.  
Am. J. Respir. Crit. Care Med. 1998, 58, 1524–1527. 
36.  Lucidi,  V.;  Ciabattoni,  G.;  Bella,  S.;  Barnes,  P.J.;  Montuschi,  P.  Exhaled  8-isoprostane  and 
prostaglandin E2 in patients with stable and unstable cystic fibrosis. Free Radical Bio. Med. 
2008, 45, 913–919. 
37.  Psathakis,  K.;  Papatheodorou,  G.;  Plataki,  M.  8-Isoprostane,  a  marker  of  oxidative  stress,  is 
increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest 2004, 
125, 1005–1011. 
38.  Carpagnano,  G.E.;  Kharitonov,  S.A.;  Resta,  O.;  Foschino-Barbaro,  M.P.;  Gramiccioni,  E.; 
Barnes, P.J. Increased 8-Isoprostane and Interleukin-6 in Breath Condensate of Obstructive Sleep 
Apnea Patients. Chest 2002, 122, 1162–1167. 
39.  Alfaro,  M.F.;  Walby,  W.F.;  Adams,  W.C.;  Schelegle,  E.S.  Breath  condensate  levels  of  
8-isoprostane  and  leukotriene  B4  after  ozone  inhalation  are  greater  in  sensitive  versus 
nonsensitive subjects. Exp. Lung Res. 2007, 33, 115–133. 
40.  MontuschiI, P.; Barnes, P.J.; Roberts, L.J., II. Isoprostanes: Markers and mediators of oxidative 
stress. FASEB J. 2004, 18, 1791–1800. 
41.  Montuschi, P.; Barnes, P.J.; Ciabattoni, G. Advanced Protocols in Oxidative Stress II; Humana 
Press: New York, NY, USA, 2009; p. 594. 
42.  Tanou,  K.;  Koutsokera,  A.;  Kiropoulos,  T.S.; Maniatiw,  M.;  Papaioannou,  A.I.;  Georga,  K.; 
Zarogiannis, S.; Gourgoulianis, K.I.; Kostikas, K. Inflammatory and oxidative stress biomarkers 
in allergic rhinitis: The effect of smoking. Clin. Exp. Allergy 2009, 39, 345–353. 
43.  Gratziou, C.; Rovina, N.; Makris, M.; Simoes, D.C.; Papapetropoulos, A.; Roussos, C. Breath 
markers  of  oxidative  stress  and  airway  inflammation  in  seasonal  allergic  rhinitis.  Int.  J. 
Immunopathol. Pharmacol. 2008, 21, 949–957. 
44.  Chow, S.; Campbell, C.; Sandrini, A.; Thomas, P.S.; Johnson, A.R.; Yates, D.H. Exhaled breath 
condensate biomarkers in asbestos-related lung disorders. Respir. Med. 2009, 103, 1091–1097. 
45.  Carraro, S.; Cogo, P.E.; Isak, I.; Simonato, M.; Corradi, M.; Carnielli, V.P.; Baraldi, E. EIA and 
GC-MS analysis of 8-isoprostane in EBC of children with problematic asthma Eur. Respir. J. 
2010, 35, 1364–1369. Int. J. Mol. Sci. 2010, 11                      
 
4656 
46.  Makris,  D.;  Paraskakis,  E.;  Korakas,  P.;  Karagiannakis,  E.;  Sourvinos,  G.;  Siafakas,  N.M.; 
Tzanakis,  N.  Exhaled  Breath  Condensate  8-Isoprostane,  Clinical  Parameters,  Radiological 
Indices and Airway Inflammation in COPD. Respiration 2008, 75, 138–144. 
47.  Hoydonck,  P.G.A.V.;  Wuyts,  W.A.;  Vanaudenaerde,  B.M.;  Schouten,  E.G.;  Dupont,  L.J.; 
Temme, E.H.M. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath 
condensate. Eur. Respir. J. 2004, 23, 189–192. 
48.  Pelclová, D.; Fenclová, Z.; Krmenciková, M.; Navratil, T.; Kuzma, M.; Kacer, P. Exhaled breath 
condensate markers of oxidant stress in patients with pneumoconioses. Chest 2008, 6001. 
49.  Piotrowski, W.J.; Kurmanowska, Z.; Antczak, A.; Marczak, J.; Górski, P. Exhaled 8-isoprostane 
as a prognostic marker in sarcoidosis. A short term follow-up. BMC Pulm. Med. 2010, 10, 1–7. 
50.  Pelclová, D.; Fenclová, Z.; Kacer, P.; Navrátil, T.; Kuzma, M.; Lebedová, J.K.; Klusácková, P. 
8-isoprostane and leukotrienes in exhaled breath condensate in Czech subjects with silicosis. Ind. 
Health 2007, 45, 766–774. 
51.  Tufvesson, E.; Bozovic, G.; Hesselstrand, R.; Bjermer, L.; Scheja, A.; Wuttge, D.M. Increased 
cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis 
patients. Rheumatology 2010, 49, 2322–2326. 
52.  Horvath, I.; Hunt, J.; Barnes, P.J. Exhaled breath condensate: methodological recommendations 
and unresolved questions. Eur. Respir. J. 2005, 26, 523–548. 
53.  Fritter, D.; Knobler, C.M. Experiments and simulation of the growth of droplets on a surface 
(breath figures). Phys. Rev. A 1991, 43, 2858–2869. 
54.  Mutlu,  G.M.;  Garey,  K.W.;  Robbins,  R.A.;  Danziger,  L.H.;  Rubinstein,  I.  Collection  and 
Analysis of Exhaled Breath Condensate in Humans. Am. J. Respir. Crit. Care Med. 2001, 164, 
731–737. 
55.  Fairchild, C.I.; Stampfer, J.F. Particle concentration in exhaled breath. Am. Ind. Hyg. Assoc. J. 
1987, 48, 948–949. 
56.  Papineni, R.S.; Rosenthal, F.S. The size distribution of droplets in the exhaled breath of healthy 
human subjects. J. Aerosol Med. 1997, 10, 105–116. 
57.  Zacharasiewicz,  A.;  Wilson,  N.;  Lex,  C.;  Li,  A.;  Kemp,  M.;  Donovan,  J.;  Hooper,  J.;  
Kharitonov, S.A.; Bush, A. Repeatability of sodium and chloride in exhaled breath condensates. 
Pediatr. Pulmonol. 2004, 37, 273–275. 
58.  Hunt, J. Exhaled breath condensate: An evolving tool for noninvasive evaluation of lung disease. 
J. Allergy Clin. Immunol. 2002, 110, 28–34. 
59.  Lema,  J.B.D.;  González,  M.;  Vigil,  L.;  Casan,  P.  Exhaled  Breath  Condensate:  Standardized 
Collection of Samples From Healthy Volunteer. Arch. Bronconeumol. 2005, 41, 584–586. 
60.  Sznajder, J.I.;  Fraiman, A.; Hall, J.B.; Sanders, W.; Schmidt,  G.; Crawford,  G.; Nahum,  A.; 
Factor, P.; Wood, L.D. Increased hydrogen peroxide in the expired breath of patients with acute 
hypoxemic respiratory failure. Chest 1989, 96, 606–612. 
61.  Rosias,  P.P.;  Robroeks,  C.M.;  Niemarkt,  H.J.;  Kester,  A.D.;  Vernooy,  J.H.;  Suykerbuyk,  J.; 
Teunissen, J.; Heynens, J.; Hendriks, H.J.; Jobsis, Q.; Dompeling, E. Breath condenser coatings 
affect  measurement  of  biomarkers  in  exhaled  breath  condensate.  Eur.  Respir.  J.  2006,  28,  
1036–1041. Int. J. Mol. Sci. 2010, 11                      
 
4657 
62.  Hoffmeyer, F.; Raulf-Heimsoth, M.; Harth, V.; Bünger, J.; Brüning, T. Comparative analysis of 
selected exhaled breath biomarkers obtained with two different temperature-controlled devices. 
BMC Pulm. Med. 2009, 9, 1–10. 
63.  Carpagnano, G.E.; Resta, O.; Foschino-Barbaro, M.P.; Spanevello, A.; Stefano, A.; Gioia, G.D.; 
Serviddio, G.; Gramiccioni, E. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive 
pulmonary  disease:  effect  of  carbocysteine  lysine  salt  monohydrate  (SCMC-Lys).  Eur.  J. 
Pharmacol. 2004, 505, 169–175. 
64.  Moloney, E.D.; Mumby, S.E.; Gajdocsi, R.; Cranshaw, J.H.; Kharitonov, S.A.; Quinlan, G.J.; 
Griffiths, M.J. Exhaled Breath Condensate Detects Markers of Pulmonary Inflammation after 
Cardiothoracic Surgery. J. Respir. Crit. Care Med. 2004, 169, 64–69. 
65.  Komakula, S.; Khatri, S.; Mermis, J.; Savill, S.; Haque, S.; Rojas, M.; Brown, L.; Teague, G.W.; 
Holguin, F. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 
8-isoprostanes in asthmatics. Respir. Res. 2007, 8, 1–10. 
66.  Ngamtrakulpanit,  L.;  Yu,  Y.;  Adjei,  A.;  Amoah,  G.;  Gaston,  B.;  Hunt,  J.F.  Identification  of 
Intrinsic Airway Acidification in Pulmonary Tuberculosis. Global J. Health Sci. 2010, 2, 106–110. 
67.  Izquierdo,  J.L.;  Almonacid,  C.;  Parra,  T.;  Pérez,  J.  Systemic  and  lung  inflammation  in  2 
phenotypes of chronic obstructive pulmonary disease. Arch. Bronconeumol. 2006, 42, 332–337. 
68.  Almonacid,  C.;  Izquierdo,  J.L.;  Parra,  T.;  Pérez,  J.  El  pH  medido en  el  condensado  de  aire 
exhalado  se  correlaciona  con  cambios  en  los  marcadores  inflamatorios  en  los  pacientes  con 
EPOC. Rev. Patol Respir. 2007, 10, 69–75. 
69.  Corradi,  M.  Exhaled  breath  condensate  in  paediatric  pulmonology.  Pneumologia  Pediatrica 
2006, 24, 12–19. 
70.  Nowak,  D.;  Kobus,  M.;  Mokwiński,  M.  Urządzenie  do  zbierania  kondensatu  pary  wodnej 
wydychanego powietrza. PL Patent 192973, 2003. 
71.  Liu,  J.;  Conrad,  D.H.;  Chow,  S.;  Tran,  V.H.;  Yates,  D.H.;  Thomas,  P.S.  Collection  devices 
influence the constituents of exhaled breath condensate. Eur. Respir. J. 2007, 30, 807–808. 
72.  Koczulla,  R.;  Dragonieri,  S.;  Schot,  R.;  Bals,  R.;  Gauw,  S.A.;  Vogelmeier,  C.;  Rabe,  K.F.;  
Sterk, P.J.; Hiemstra, P.S. Comparison of exhaled breath condensate pH using two commercially 
available devices in healthy controls, asthma and COPD patients. Respir. Res. 2009, 10, 1–8. 
73.  ValenzuelaI, O.F.A.; Encina, M.P.S. Design and evaluation of a device for collecting exhaled 
breath condensate. J. Bras. Pneumol. 2009, 35, 69–72. 
74.  Effros, R.M.; Dunning, M.B., III.; Biller, J.; Shaker, R. The promise and perils of exhaled breath 
condensates. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287, L1073–L1080. 
75.  Rosias,  P.P.R.;  Robroeks,  C.M.;  Kant,  K.D.V.D.;  Rijkers,  G.T.;  Zimmermann,  L.J.;  Schayck, 
C.P.V.; Heynens, J.W.; Jobsis, Q.; Dompeling, E. Feasibility of a new method to collect exhaled 
breath condensate in pre-school children. Pediatr. Allergy Immunol. 2010, 21, 235–244. 
76.  Gaber,  F.;  Acevedo, F.; Delin, I.;  Sundblad,  B.M.; Palmberg, L.; Larsson, K.; KumLin,  M.; 
Dahlen,  S.E.  Saliva  is  one  likely  source  of  leukotriene  B4  in  exhaled  breath  condensate.  
Eur. Respir. J. 2006, 28, 1229–1235. 
77.  Effros, R.M.; Peterson, B.; Casaburi, R.; Su, J.; Dunning, M.; Torday, J.; Biller, J.; Shaker, R. 
Epithelial  lining  fluid  solute  concentrations  in  chronic  obstructive  lung  disease  patients  and 
normal subjects. J. Appl. Physiol. 2005, 99, 1286–1292. Int. J. Mol. Sci. 2010, 11                      
 
4658 
78.  Huszar, E.; Vass, G.; Vizi, E.; Csoma, Z.; Barat, E.; Molnar, V.G.; Herjavecz, I.; Horvath, I. 
Adenosine  in  exhaled  breath  condensate  in  healthy  volunteers  and  in  patients  with  asthma.  
Eur. Respir. J. 2002, 20, 1393–1398. 
79.  Kharitonov, S.A.; Barnes, P.J. Exhaled Markers of Pulmonary Disease. Am. J. Respir. Crit. Care 
Med. 2001, 163, 1693–1722. 
80.  Griese,  M.; Noss, J.; Bredow, C.V. Protein pattern  of exhaled breath condensate and  saliva. 
Proteomics 2002, 2, 690–696. 
81.  Reinhold,  P.;  Knobloch,  H.  Exhaled  breath  condensate:  Lessons  learned  from  veterinary 
medicine. J. Breath Res. 2010, 4, 017001. 
82.  Vaughan, J.; Ngamtrakulpanit, L.; Pajewski, T.N.; Turner, R.; Nguyen, T.-A.; Smith, A.; Urban, 
P.; Hom, S.; Gaston, B.; Hunt, J. Exhaled breath condensate pH is a robust and reproducible 
assay of airway acidity. Eur. Respir. J. 2003, 22, 889–894. 
83.  Svensson, S.; Olin, A.-C.; Larstad, M.; Ljungkvist, G.; Toren, K. Determination of hydrogen 
peroxide in exhaled breath condensate by flow injection analysis with fluorescence detection.  
J. Chromatogr. B 2004, 809, 199–203. 
84.  Gessner,  C.;  Scheibe,  R.;  Wotzel,  M.;  Hammerschmidt,  S.;  Kuhn,  H.;  Engelmann,  L.;  
Hoheisel, G.; Gillissen, A.; Sack, U.; Wirtz, H. Exhaled breath condensate cytokine patterns in 
chronic obstructive pulmonary disease. Respir. Med. 2005, 99, 1229–1240. 
85.  Syslová, K.; Kačer, P.; Kuzma, M.; Pankrácová, A.; Fenclová, Z.; Vlčková, Š.; Lebedová, J.; 
Pelclová, D. LC-ESI-MS/MS method for oxidative stress multimarker screening in the exhaled 
breath condensate of asbestosis/silicosis patients. J. Breath Res. 2010, 4, 017104. 
86.  Wells, K.; Vaughan, J.; Pajewski, T.N.; Hom, S.; Ngamtrakulpanit, L.; Smith, A.; Ngujen, A.; 
Turner, R. Exhaled breath condensate pH assays are not influenced by oral amonia. Thorax 2005, 
60, 27–31. 
87.  Goldoni, M.; Caglieri, A.; Andreoli, R.; Poli, D.; Manini, P.; Vettori, M.V.; Mutti, A. Influence of 
condensation  temperature  on  selected  exhaled  breath  parameters.  BMC  Pulm.  Med.  2005,  5,  
1–9. 
88.  White, D.C.; Geyer, R.; Cantu, J.; Jo, S.-C.; Peacock, A.D.; Saxton, A.M.; Mani, S.; Jett, M.; 
Moss,  O.R.  Feasibility  of  assessment  of  regulatory  lipids  in  breath  condensate  as  potential 
presymptomatic harbingers of pulmonary pathobiology. J. Microbiol. Methods 2005, 62, 293–302. 
89.  Syslová, K.; Kačer, P.; Kuzma, M.; Najmanová, V.; Fenclová, Z.; Vlčková, Š.; Lebedová, J.; 
Pelclová, D. Rapid and easy method for monitoring oxidative stress markers in body fluids of 
patients with asbestos or silica-induced lung diseases. J. Chromatogr. B 2009, 877, 2477–2486. 
90.  Montuschi, P.; Ragazzoni, E.; Valente, S.; Corbo, G.; Mondino, C.; Ciappi, G.; Ciabattoni, G. 
Validation of 8-isoprostane and prostaglandin E2 measurements. Inflamm. Res. 2003, 52, 502–507. 
91.  Montuschi,  P.;  Mondino,  C.;  Koch,  P.;  Barnes,  P.J.;  Ciabattoni,  G.  Effects  of  a  leukotriene 
receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J. Allergy 
Clin. Immunol. 2006, 118, 347–353. 
92.  Piotrowski,  W.J.;  Antczak,  A.;  Marczak,  J.;  Nawrocka,  A.;  Kurmanowska,  Z.;  Górski,  P. 
Eicosanoids in Exhaled Breath Condensate and BAL fluid of patients with sarkoidosis. Chest 
2007, 132, 589–596. Int. J. Mol. Sci. 2010, 11                      
 
4659 
93.  Li, Y.; Chongsuvivatwong, V.; Geater, A.; Liu, A. Exhaled breath condensate cytokine level as a 
diagnostic tool for obstructive sleep apnea syndrome. Sleep Med. 2009, 10, 95–103. 
94.  Ko,  F.W.S.;  Lau,  C.Y.K.;  Leung,  T.F.;  Wong,  G.W.K.;  Lam,  C.W.K.;  Hui,  D.S.C.  Exhaled 
breath  condensate  levels  of  8-isoprostane,  growth  related  oncogene  a  and  monocyte 
chemoattractant protein-1 in patients with chonic obstructive pulmonary disease. Respir. Med. 
2006, 100, 630–638. 
95.  Dalaveris, E.; Kerenidi, T.; Katsabeki-Katsafli, A.; Kiropoulos, T.; Tanou, K.; Gourgoulianis, K. 
I.; Kostikas, K. VEGF, TNFa and 8-isoprostane levels in exhaled breath condensate and serum of 
patients with lung cancer. Lung Cancer 2009, 64, 219–225. 
96.  Gonzalez-Reche, L.M.; Schaefer, D.; Göen, T.; Kraus, T. Validity Assessment for the Results of 
Three Inflammatory Markers in Exhaled Breath Condensate—A Pilot Study. Chromatographia 
2009, 70, 1387–1392. 
97.  Holz,  O.  New  Perspectives  in  Monitoring  Lung  Inflammation:  Analysis  of  Exhaled  Breath 
Condensate; CRC Press LLC: Washington, DC, USA, 2005. 
98.  Lee,  C.-Y.J.;  Huang,  S.H.;  Jenner,  A.M.;  Halliwell,  B.  Measurement  of  F2-isoprostanes, 
hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radical 
Bio. Med. 2008, 44, 1314–1322. 
99.  Limb,  S.L.;  Hubbard,  W.C.;  Wood,  R.A.;  Adkinson,  N.,  Jr.  Asthma  Biomarkers  in  Exhaled 
Breath Condensate (EBC). J. Allergy Clin. Immunol. 2006, 117, 194. 
100.  Montuschi,  P.;  Barnes,  P.J.  Analysis  of  exhaled  breath  condensate  for  monitoring  airway 
inflammation. Trends Pharmacol. Sci. 2002, 23, 232–237. 
101.  Grob, N.M.; Aytekin, M.; Dweik, R.A. Biomarkers in exhaled breath condensate: A review of 
collection, processing and analysis. J. Breath Res. 2008, 2, 037004. 
102.  Carraro,  S.;  Rezzi,  S.;  Reniero,  F.;  Héberger,  K.;  Giordano,  G.;  Zanconato,  S.;  Guillou,  C.; 
Baraldi, E. Metabolomics Applied to Exhaled Breath Condensate in Childhood Asthma. Am. J. 
Respir. Crit. Care Med. 2007, 175, 986–990. 
103.  Laurentiis,  G.D.;  Paris,  D.;  Melck,  D.;  Maniscalco,  M.;  Marsico,  S.;  Corso,  G.;  Motta,  A.;  
Sofia, M. Metabonomic analysis of Exhaled Breath Condensate in adults by nuclear magnetic 
resonance spectroscopy. Eur. Respir. J. 2008, 32, 1175–1183. 
©  2010  by  the authors;  licensee  MDPI, Basel,  Switzerland.  This article  is  an  open  access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 